KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
RBC Capital Positive on Kempharm (KMPH) Amid KP201 Tamper Study Results
September 30, 2015 2:19 PM EDTRBC Capital analyst Randall Stanicky reiterated an Outperform rating and $22 price target on Kempharm (NASDAQ: KMPH) as new KP201 abuse-deterrent data add further support to product differentiation.
Stanicky commented, "This morning, KMPH released results of three tamper studies which showed KP201 holding up... More
KemPharm (KMPH) Issues Positive Update on KP201/APAP in Tamper Resistance
September 30, 2015 7:33 AM EDTKemPharm (NASDAQ: KMPH) reported positive results from three distinct studies designed to evaluate the tamper-resistant properties of its lead opioid prodrug KP201/APAP, KemPharm's prodrug of hydrocodone in combination with acetaminophen (APAP) compared to a generic hydrocodone bitartrate/APAP product (HB/APAP). The studies were designed based on feedback from the U.S. Food and Drug Administration (FDA). KemPharm believes that, together with the positive data from KemPharm's previous human abuse liability trials, these results may support FDA Category 1 abuse-deterrent language in the KP201/APAP product label, if approved by the... More
